Literature DB >> 32524819

Potent and Prolonged Innate Immune Activation by Enzyme-Responsive Imidazoquinoline TLR7/8 Agonist Prodrug Vesicles.

Bi Wang1, Simon Van Herck2, Yong Chen2, Xiangyang Bai1, Zifu Zhong3, Kim Deswarte4, Bart N Lambrecht4,5, Niek N Sanders3, Stefan Lienenklaus6, Hans W Scheeren1, Sunil A David7, Fabian Kiessling1, Twan Lammers1,8,9, Bruno G De Geest2, Yang Shi1.   

Abstract

Synthetic immune-stimulatory drugs such as agonists of the Toll-like receptors (TLR) 7/8 are potent activators of antigen-presenting cells (APCs), however, they also induce severe side effects due to leakage from the site of injection into systemic circulation. Here, we report on the design and synthesis of an amphiphilic polymer-prodrug conjugate of an imidazoquinoline TLR7/8 agonist that in aqueous medium forms vesicular structures of 200 nm. The conjugate contains an endosomal enzyme-responsive linker enabling degradation of the vesicles and release of the TLR7/8 agonist in native form after endocytosis, which results in high in vitro TLR agonist activity. In a mouse model, locally administered vesicles provoke significantly more potent and long-lasting immune stimulation in terms of interferon expression at the injection site and in draining lymphoid tissue compared to a nonamphiphilic control and the native TLR agonist. Moreover, the vesicles induce robust activation of dendritic cells in the draining lymph node in vivo.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32524819      PMCID: PMC7116109          DOI: 10.1021/jacs.0c01928

Source DB:  PubMed          Journal:  J Am Chem Soc        ISSN: 0002-7863            Impact factor:   15.419


  42 in total

1.  Benzaldehyde-functionalized polymer vesicles.

Authors:  Guorong Sun; Huafeng Fang; Chong Cheng; Peng Lu; Ke Zhang; Amy V Walker; John-Stephen A Taylor; Karen L Wooley
Journal:  ACS Nano       Date:  2009-03-24       Impact factor: 15.881

2.  Novel reporter mouse reveals constitutive and inflammatory expression of IFN-beta in vivo.

Authors:  Stefan Lienenklaus; Marius Cornitescu; Natalia Zietara; Marcin Łyszkiewicz; Nelson Gekara; Jadwiga Jabłónska; Frank Edenhofer; Klaus Rajewsky; Dunja Bruder; Martin Hafner; Peter Staeheli; Siegfried Weiss
Journal:  J Immunol       Date:  2009-08-10       Impact factor: 5.422

3.  Sustained antigen availability during germinal center initiation enhances antibody responses to vaccination.

Authors:  Hok Hei Tam; Mariane B Melo; Myungsun Kang; Jeisa M Pelet; Vera M Ruda; Maria H Foley; Joyce K Hu; Sudha Kumari; Jordan Crampton; Alexis D Baldeon; Rogier W Sanders; John P Moore; Shane Crotty; Robert Langer; Daniel G Anderson; Arup K Chakraborty; Darrell J Irvine
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-04       Impact factor: 11.205

4.  Self-immolative polymersomes for high-efficiency triggered release and programmed enzymatic reactions.

Authors:  Guhuan Liu; Xiaorui Wang; Jinming Hu; Guoying Zhang; Shiyong Liu
Journal:  J Am Chem Soc       Date:  2014-05-07       Impact factor: 15.419

5.  pH-degradable imidazoquinoline-ligated nanogels for lymph node-focused immune activation.

Authors:  Lutz Nuhn; Nane Vanparijs; Ans De Beuckelaer; Lien Lybaert; Glenn Verstraete; Kim Deswarte; Stefan Lienenklaus; Nikunj M Shukla; Alex C D Salyer; Bart N Lambrecht; Johan Grooten; Sunil A David; Stefaan De Koker; Bruno G De Geest
Journal:  Proc Natl Acad Sci U S A       Date:  2016-07-05       Impact factor: 11.205

Review 6.  Approaches to treat immune hot, altered and cold tumours with combination immunotherapies.

Authors:  Jérôme Galon; Daniela Bruni
Journal:  Nat Rev Drug Discov       Date:  2019-03       Impact factor: 84.694

7.  An Enzyme-Directed Imidazoquinoline for Cancer Immunotherapy.

Authors:  Joseph D Hantho; Timothy A Strayer; Amy E Nielsen; Rock J Mancini
Journal:  ChemMedChem       Date:  2016-10-11       Impact factor: 3.466

8.  One-Shot Immunomodulatory Nanodiamond Agents for Cancer Immunotherapy.

Authors:  Yu Zhang; Zhifen Cui; Huating Kong; Kai Xia; Liang Pan; Jiang Li; Yanhong Sun; Jiye Shi; Lihua Wang; Ying Zhu; Chunhai Fan
Journal:  Adv Mater       Date:  2016-02-02       Impact factor: 30.849

9.  Development of Adamantane-Conjugated TLR7/8 Agonists for Supramolecular Delivery and Cancer Immunotherapy.

Authors:  Christopher B Rodell; Maaz S Ahmed; Christopher S Garris; Mikael J Pittet; Ralph Weissleder
Journal:  Theranostics       Date:  2019-11-26       Impact factor: 11.556

10.  Peptide-TLR-7/8a conjugate vaccines chemically programmed for nanoparticle self-assembly enhance CD8 T-cell immunity to tumor antigens.

Authors:  Geoffrey M Lynn; Christine Sedlik; Faezzah Baharom; Yaling Zhu; Ramiro A Ramirez-Valdez; Vincent L Coble; Kennedy Tobin; Sarah R Nichols; Yaakov Itzkowitz; Neeha Zaidi; Joshua M Gammon; Nicolas J Blobel; Jordan Denizeau; Philippe de la Rochere; Brian J Francica; Brennan Decker; Mateusz Maciejewski; Justin Cheung; Hidehiro Yamane; Margery G Smelkinson; Joseph R Francica; Richard Laga; Joshua D Bernstock; Leonard W Seymour; Charles G Drake; Christopher M Jewell; Olivier Lantz; Eliane Piaggio; Andrew S Ishizuka; Robert A Seder
Journal:  Nat Biotechnol       Date:  2020-01-13       Impact factor: 68.164

View more
  12 in total

1.  Ultrasound-directed enzyme-prodrug therapy (UDEPT) using self-immolative doxorubicin derivatives.

Authors:  Karolin Roemhild; Helena C Besse; Bi Wang; Quim Peña; Qingxue Sun; Daiki Omata; Burcin Ozbakir; Clemens Bos; Hans W Scheeren; Gert Storm; Josbert M Metselaar; Haijun Yu; Ruth Knüchel-Clarke; Fabian Kiessling; Chrit T W Moonen; Roel Deckers; Yang Shi; Twan Lammers
Journal:  Theranostics       Date:  2022-06-06       Impact factor: 11.600

2.  Multifunctional AIE iridium (III) photosensitizer nanoparticles for two-photon-activated imaging and mitochondria targeting photodynamic therapy.

Authors:  Xuzi Cai; Kang-Nan Wang; Wen Ma; Yuanyuan Yang; Gui Chen; Huijiao Fu; Chunhui Cui; Zhiqiang Yu; Xuefeng Wang
Journal:  J Nanobiotechnology       Date:  2021-08-23       Impact factor: 10.435

Review 3.  Nanomedicine-enabled chemotherapy-based synergetic cancer treatments.

Authors:  Wencheng Wu; Yinying Pu; Jianlin Shi
Journal:  J Nanobiotechnology       Date:  2022-01-04       Impact factor: 10.435

Review 4.  Stimuli-Responsive Polymeric Nanomaterials for the Delivery of Immunotherapy Moieties: Antigens, Adjuvants and Agonists.

Authors:  Raveena Nagareddy; Reju George Thomas; Yong Yeon Jeong
Journal:  Int J Mol Sci       Date:  2021-11-19       Impact factor: 5.923

5.  Self-Stabilized Supramolecular Assemblies Constructed from PEGylated Dendritic Peptide Conjugate for Augmenting Tumor Retention and Therapy.

Authors:  Xiuli Zheng; Dayi Pan; Xiaoting Chen; Lei Wu; Miao Chen; Wenjia Wang; Hu Zhang; Qiyong Gong; Zhongwei Gu; Kui Luo
Journal:  Adv Sci (Weinh)       Date:  2021-10-07       Impact factor: 16.806

Review 6.  Stimuli-Responsive Nanoparticles for Controlled Drug Delivery in Synergistic Cancer Immunotherapy.

Authors:  Jin Zhang; Yandai Lin; Zhe Lin; Qi Wei; Jiaqi Qian; Renjie Ruan; Xiancai Jiang; Linxi Hou; Jibin Song; Jianxun Ding; Huanghao Yang
Journal:  Adv Sci (Weinh)       Date:  2021-12-19       Impact factor: 16.806

Review 7.  Stimulus-responsive self-assembled prodrugs in cancer therapy.

Authors:  Xiao Dong; Rajeev K Brahma; Chao Fang; Shao Q Yao
Journal:  Chem Sci       Date:  2022-03-18       Impact factor: 9.825

8.  Safe and efficient 2D molybdenum disulfide platform for cooperative imaging-guided photothermal-selective chemotherapy: A preclinical study.

Authors:  Xin Li; Lingdan Kong; Wei Hu; Changchang Zhang; Andrij Pich; Xiangyang Shi; Xipeng Wang; Lingxi Xing
Journal:  J Adv Res       Date:  2021-08-11       Impact factor: 12.822

Review 9.  Recent Advancements in Nanomedicine for 'Cold' Tumor Immunotherapy.

Authors:  Qinjun Chen; Tao Sun; Chen Jiang
Journal:  Nanomicro Lett       Date:  2021-03-16

Review 10.  Evolution of Toll-like receptor 7/8 agonist therapeutics and their delivery approaches: From antiviral formulations to vaccine adjuvants.

Authors:  Sachin Bhagchandani; Jeremiah A Johnson; Darrell J Irvine
Journal:  Adv Drug Deliv Rev       Date:  2021-05-29       Impact factor: 15.470

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.